NVIDIA: Investment Portfolio & Startup News
NVIDIA
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Basecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Basecamp Research trains biological foundation models, called EDEN, on a proprietary genomic dataset spanning more than 30 countries. The models are used to design therapeutics, starting with in vivo cell therapies that reprogram a patient's cells inside the body to treat conditions such as cancer and autoimmune disease.
PhysicsX announces its £225m Series C led by Temasek to accelerate physics AI for deep tech manufacturing
PhysicsX builds an AI-native engineering platform that predicts physical behaviour in seconds rather than hours or days, enabling industrial engineering teams to evaluate far more design variants across the product lifecycle. The platform serves organisations in aerospace and defence, semiconductors, automotive, energy, and materials manufacturing.
Recursive Superintelligence raises £480m led by GV and Greycroft for AI systems that conduct automated scientific discovery
Recursive Superintelligence is a London-based AI research startup developing systems that conduct experiments to improve themselves through automated scientific discovery. The platform is designed to explore recursive self-improvement while focusing on AI safety and capability discovery.
Ineffable Intelligence lands over £800m in a seed round led by Sequoia and Lightspeed to develop superintelligence with reinforcement learning
Ineffable Intelligence is an AI research startup developing systems that learn from their own experience to discover new knowledge. It focuses on building a “superlearner” designed to advance reinforcement learning and scientific discovery.
Nscale raises £1.5bn Series C led by Aker ASA and 8090 Industries to deploy AI infrastructure globally
Nscale designs and operates AI-native data centres, providing vertically integrated compute, networking and software infrastructure that addresses GPU shortages while delivering compliant, renewable-powered capacity for enterprise and national AI workloads.
Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug
Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.
More venture news
- 15 Oct 2026
OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences - 30 Sept 2026
MetaviewMetaview unlocks a £45m Series C led by Insight Partners to automate hiring with sourcing and screening agents
Series CHR - 23 Sept 2026
Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences
